title: The ratio of androstenedione:11 beta-hydroxyandrostenedione is an important marker of adrenal androgen excess in women.
abstract: OBJECTIVE
  To determine if the ratio of serum androstenedione (A):11 beta-hydroxyandrostenedione (OHA) would be helpful in differentiating adrenal from ovarian hyperandrogenism.
  
  
  METHODS
  Prospective study of outpatients being evaluated for hyperandrogenism.
  
  
  METHODS
  Normal women (n = 27), those with hyperandrogenic chronic anovulation (n = 25), and 7 with adult onset of congenital adrenal hyperplasia (CAH) because of 21-hydroxylase deficiency.
  
  
  METHODS
  Fasting serum between 8:00 A.M. and 9:00 A.M. Patients with hyperandrogenic chronic anovulation and CAH received dexamethasone (DEX) 2 mg for 7 days.
  
  
  METHODS
  Serum testosterone (T), unbound T, dehydroepiandrosterone sulfate (DHEAS), A, and 11 beta-OHA by radioimmunoassay.
  
  
  RESULTS
  Serum 11 beta-OHA and DHEAS were elevated in 52% and 40% of patients with hyperandrogenic chronic anovulation and in 7 of 7 and 1 of 7 patients with CAH. The ratio of A:11 beta-OHA was significantly higher (P less than 0.05) in hyperandrogenic chronic anovulation and significantly lower (P less than 0.05) in CAH compared with controls. Serum A:11 beta-OHA correlated with T (r = 0.58, P less than 0.05). The ratios of A:11 beta-OHA were similar and significantly lower in CAH and hyperandrogenic chronic anovulation patients who were DEX sensitive compared with those who were not DEX sensitive. The ratio correlated with the percentage suppression of T, unbound T, and A after DEX (P less than 0.01). There were no differences with measurements of DHEAS and 11 beta-OHA. Using the mean ratio of controls (1.3) as a cutoff value, the sensitivity of the A:11 beta-OHA in detecting adrenal hyperandrogenism, as assessed by DEX sensitivity, was 100%, the specificity was 84%, and the predictive value was 67%.
  
  
  CONCLUSIONS
  The ratio of A:11 beta-OHA appears to be an excellent marker for identifying patients with adrenal hyperandrogenism and CAH.
authors.affiliation: Cattedra di Endocrinologia, Universita di Palermo, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Carmina
authors.forename: F Z
authors.initials: FZ
authors.lastname: Stanczyk
authors.forename: L
authors.initials: L
authors.lastname: Chang
authors.forename: R A
authors.initials: RA
authors.lastname: Miles
authors.forename: R A
authors.initials: RA
authors.lastname: Lobo
mesh_terms: D000293:Adolescent; D000307:Adrenal Gland Diseases / Q000097:blood / Q000175:diagnosis; D000311:Adrenal Glands / Q000378:metabolism* / Q000473:pathology; D000312:Adrenal Hyperplasia, Congenital; D000328:Adult; D000728:Androgens / Q000378:metabolism*; D000735:Androstenedione / Q000031:analogs & derivatives* / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology; D011446:Prospective Studies; D011863:Radioimmunoassay
chemical_list: D000728:Androgens; D015415:Biomarkers; D000735:Androstenedione; C003582:11-hydroxyandrostenedione; D003907:Dexamethasone